Diabetic Peripheral Neuropathy Pipeline Analysis Report 2025

Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM), affecting approximately 50% of diabetic patients. It causes nerve damage, leading to pain, numbness, and sensory loss, significantly impacting patients' quality of life. With the increasing prevalence of diabetes, the demand for advanced diabetic peripheral neuropathy therapeutics is rising. The pipeline for DPN drugs is expanding, focusing on alternative therapies that provide effective pain relief and nerve protection. Growing research initiatives and technological advancements are expected to drive market growth in the coming years, offering promising diabetic peripheral neuropathy drug candidates and improved treatment options.

Report Coverage

The Diabetic Peripheral Neuropathy Pipeline Insight Report by the publisher gives comprehensive insights into diabetic peripheral neuropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic peripheral neuropathy. The diabetic peripheral neuropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diabetic peripheral neuropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diabetic peripheral neuropathy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diabetic peripheral neuropathy.

Diabetic Peripheral Neuropathy Pipeline Outlook

Diabetic peripheral neuropathy is a common complication of diabetes caused by prolonged high blood sugar levels, damaging peripheral nerves. It typically affects the feet and legs, leading to numbness, tingling, pain, or weakness. Poor blood circulation and metabolic factors also contribute to nerve damage, increasing the risk of infections, ulcers, and mobility issues in severe cases.

Diabetic peripheral neuropathy treatments focus on managing symptoms and slowing progression. Blood sugar control is crucial to prevent further nerve damage. Medications like antidepressants, anticonvulsants, and pain relievers provide symptom relief. Lifestyle changes, including regular exercise and a balanced diet, are recommended. In advanced cases, physical therapy and specialized foot care help maintain function and prevent complications. Lyrica (pregabalin), Cymbalta (duloxetine), Nucynta (tapentadol), and Qutenza (capsaicin) are currently approved by the Food and Drug Administration for treating pain associated with diabetic peripheral neuropathy.

Diabetic Peripheral Neuropathy Epidemiology

Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM), affecting approximately 50% of diabetic patients, depending on disease duration and glucose control. In 2021, 38.4 million people in the United States (11.6% of the population) had diabetes. The United Kingdom reported 4.3 million cases. India had over 74 million diabetics in 2021, projected to exceed 124 million by 2045.

Diabetic Peripheral Neuropathy - Pipeline Therapeutic Assessment

This section of the report covers the analysis of diabetic peripheral neuropathy drug candidates based on several segmentations, including:

By Phase

The pipeline report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The diabetic peripheral neuropathy pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Gene Therapies
• Monoclonal Antibodies
• Peptides
• Recombinant Fusion Proteins

By Route of Administration

The pipeline assessment covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Diabetic Peripheral Neuropathy - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases.

According to analysis, phase II with 57.89%, covers a major share of the total diabetic peripheral neuropathy clinical trials. Phase III holds 18.42%, indicating advancement toward regulatory approval. Phase I and phase IV contribute around 10.53%, reflecting a balanced focus on early-stage safety and post-marketing studies. Early phase I represents 2.63%. This robust pipeline can positively accelerate innovation and market growth in diabetic peripheral neuropathy treatment.

Diabetic Peripheral Neuropathy Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the diabetic peripheral neuropathy pipeline analysis include small molecules, gene therapies, monoclonal antibodies, peptides, and recombinant fusion proteins. The diabetic peripheral neuropathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic peripheral neuropathy. Sodium channel inhibitors are emerging as a novel drug class for diabetic peripheral neuropathy (DPN). For example, Suzetrigine (VX-548), an oral selective NaV1.8 pain signal inhibitor, is advancing in the pipeline. The compound also holds a breakthrough therapy designation from the United States Food and Drug Administration.

Diabetic Peripheral Neuropathy Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the diabetic peripheral neuropathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diabetic peripheral neuropathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diabetic peripheral neuropathy clinical trials:

• Eli Lilly and Company
• Eurofarma Laboratorios S.A.
• Vertex Pharmaceuticals Incorporated
• Lexicon Pharmaceuticals
• Jemincare
• Haisco Pharmaceutical Group Co., Ltd.
• SK Chemicals Co., Ltd.
• Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
• Novo Nordisk A/S, Syqe Medical
• Merz Pharmaceuticals GmbH

Diabetic Peripheral Neuropathy Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for diabetic peripheral neuropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diabetic peripheral neuropathy drug candidates.

Drug: N0750

N0750 is an investigational drug candidate developed by Eurofarma Laboratórios S.A. It is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in treating painful diabetic peripheral neuropathy (PDPN). This study aims to determine whether N0750 is superior to monotherapies like Cymbalta® (duloxetine) and Lyrica® (pregabalin) in reducing pain intensity over 12 weeks. The trial is expected to enroll 666 patients and conclude by March 2028.

Drug: LY3556050

LY3556050, developed by Eli Lilly and Company, is currently being evaluated in a Phase 2 clinical trial for diabetic peripheral neuropathic pain (DPNP). This study aims to assess the safety and efficacy of LY3556050 compared to a placebo over approximately 24 weeks. LY3556050 likely targets specific pain pathways, potentially reducing pain signals and improving patient outcomes. The study completion is estimated by July 2025, with 410 participants enrolled. LY3556050 is a selective SSTR4 agonist that targets peripheral nociceptive pathways, aiming to reduce chronic diabetic peripheral neuropathic pain through oral administration._x000D_

Drug: YJ001

YJ001 for Spray Use is a topical drug sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. This Phase I, randomized, double-blind, placebo-controlled study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of YJ001 in patients with diabetic peripheral neuropathic pain (DPNP). The drug is administered as multiple sprays on both feet to determine the optimal therapeutic dose for effective pain relief. YJ001 is a topical spray that helps in reducing diabetic neuropathic pain by delivering localized relief while minimizing systemic exposure and side effects._x000D_

Key Questions Answered in the Diabetic Peripheral Neuropathy Pipeline Insight Report

• Which companies/institutions are leading the diabetic peripheral neuropathy drug development?
• What is the efficacy and safety profile of diabetic peripheral neuropathy pipeline drugs?
• Which company is leading the diabetic peripheral neuropathy pipeline development activities?
• What is the current diabetic peripheral neuropathy commercial assessment?
• What are the opportunities and challenges present in the diabetic peripheral neuropathy pipeline landscape?
• What is the efficacy and safety profile of diabetic peripheral neuropathy pipeline drugs?
• Which company is conducting major trials for diabetic peripheral neuropathy drugs?
• Which companies/institutions are involved in diabetic peripheral neuropathy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in diabetic peripheral neuropathy?

Reasons To Buy This Report

The Diabetic Peripheral Neuropathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic peripheral neuropathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic peripheral neuropathy collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.